BloodSurf 2016: Blood-Biomaterial Interactions

BloodSurf 2016：血液与生物材料的相互作用

• 批准号: 9125521
• 负责人: ROBERT A LATOUR
• 金额: $ 2万
• 依托单位: CLEMSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2017-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9125521
• 关键词: Address; Adverse effects; Anticoagulation; Antiplatelet Drugs; Area; Aspirin; Award; Back; Biocompatible Materials; Biomaterials Research; Blood; Blood Platelets; Blood Vessels; Blood coagulation; Cardiovascular Diseases; Cardiovascular system; Catheters; Clinical; Coagulation Process; Collaborations; Communities; Comorbidity; Complex; Development; Device or Instrument Development; Devices; Diabetes Mellitus; Disabled Persons; Discipline; Disease; Engineering; Event; Fostering; Funding; Goals; Hematologist; Hematology; Hemorrhage; Hemostatic function; Heparin; In Vitro; Inflammation; Inflammatory; International; Joints; Lead; Learning; Link; Location; Mechanics; Mediating; Medical Device; Medical Students; Medicine; Membrane Proteins; Minority; Modern Medicine; Molecular; Oral; Patient Monitoring; Patients; Pharmaceutical Preparations; Plavix; Postdoctoral Fellow; Reaction; Research; Research Personnel; Resistance; Schedule; Scientist; Seasons; Stents; Structure; Students; Surface; System; Testing; Therapeutic; Thrombosis; Thrombus; Travel; Universities; Vascular Diseases; Warfarin; Whole Blood; Woman; blood oxygenator; clinically significant; clopidogrel; cost; design; effective therapy; falls; improved; in vivo; interest; medical schools; meetings; professor; research study; response; symposium; ventricular assist device

 DESCRIPTION (provided by applicant): Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease, ranging from relatively simple catheters, balloons, and stents to complex mechanical systems such as ventricular assist devices (VADs). While antithrombotic and antiplatelet drugs, such as heparin and clopidogrel (Plavix), are commonly used to suppress biomaterial-induced thrombus formation for patients undergoing treatment with such devices, these types of drugs inhibit blood coagulation systemically, which can lead to other clinically significant bleeding-related complications. More effective treatments for cardiovascular and vascular disease would be provided from the development of thrombus-resistant biomaterials that would eliminate, or at least greatly reduce, the need for the use of systemic antithrombotic therapies. However, a limited understanding of the specific mechanisms underlying thrombotic reactions to synthetic materials following their contact with blood continues to hinder the development of new clinical devices and treatments for cardiovascular and vascular disorders. Addressing this problem requires the efforts of researchers and practitioners from diverse fields-in particular, this requires close interaction between biologists chemists, physicists, and engineers with clinical practitioners. The specific purpose of the BloodSurf 2016 Symposium (September 13-16, 2016, Babson Executive Conference Center, Wellesley, MA) is to bring together experts from these respective disciplines along with students and postdoctoral fellows who share a common interest in the development of thrombo-resistant biomaterials for four days immersed in presentations and discussions about the critical needs and research directions for the development of medical devices with improved blood compatibility. Recognizing the key role of platelets in mediating blood response to biomaterials and the need for closer integration with scientists and clinicians within the general hemostasis and thrombosis community, this symposium will be linked with the 9th Platelets International Symposium that is being coordinated by Dr. Alan D. Michelson, Director for Platelet Research Studies and Professor of Medicine, Harvard Medical School, and Dr. David Varon, Professor of Hematology, Hebrew University of Jerusalem. The Platelets International Symposium will follow BloodSurf 2016, including a one-day set of combined sessions. Because BloodSurf 2016 represents a unique meeting that falls outside of the normally scheduled set of professional conferences held each year, funding support is requested to offset the costs of attendance for our set of 16 invited speakers as well as providing eight student/postdoc travel awards (four of which will be set aside for the support of women, minorities, and persons with disabilities). Narrative: Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease. The BloodSurf 2016 Symposium will bring together leading scientists, engineers, and clinicians interested in improving the blood compatibility of blood-contacting medical devices for four days of focused presentations and discussions. Funding support is requested to offset travel costs for our set of 16 invited speakers and to provide eight travel awards for students and postdoctoral fellows to attend this symposium.

 描述（申请人证明）：生物材料引起的透明是所有在催泪质和血管疾病中的血液接触式疾病所共有的临床证明，从相对简单的导管诸如心室辅助设备（VADS）等相对简单导管范围。 - 抗性的生物材料消除了E，需要使用全身性抗血栓形成疗法。问题要求研究人员和从业人员的各种领域的雇员特别是在生物学家化学家之间的密切相互作用。是为了汇集Shaos学生和博士后研究员的专家，他们共享耐铁龙的生物材料四天，沉浸在有关上毒的需求和研究DH的指示中，并指示医疗设备的前任医疗设备的作用，以改善血液兼容的血小板在调解血小板的关键作用在调解血液反应中的重要作用需要更紧密的融合，由止血和血栓形成社区内部，由耶路撒冷希伯来语大学的哈佛医学院研究主任Alan D. Michelson博士协调研讨会将遵循2016年的BloodSurf，包括一组一组合并的会议。演讲者作为提供八项学生/博士后旅行奖（其中四项将由妇女，少数民族和残疾人的支持）。 叙述：生物剂引起的血栓形成是所有接触性血管疾病和血管疾病的信任的杂物。 。